Drug intelligence / Profile preview

AEX-02

Development stage: Preclinical
Lead developer: Aethox Therapeutics
Modality: Small Molecules

Overview

AEX-02, also identified by the program code AX 103, is a discovery-stage oncology asset under development by Aethox Therapeutics. The drug is intended for the treatment of solid tumors, likely utilizing a macrophage-mediated mechanism of action to alter the immune landscape of the tumor microenvironment. Although the specific target and modality have not been formally disclosed by the sponsor, the program represents Aethox's efforts in leveraging innate immunity for cancer therapy. It is currently presumed to be a small molecule based on early pipeline characterizations.

Beyond the preview

Go deeper on AEX-02.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AEX-02.

Explore the full profile